Consistent with this, adjuvant treatment of human epidermal growth factor receptor-2 positive (HER2+) breast cancer with the anti-HER2 monoclonal antibody (mAb) trastuzumab (Herceptin®) increases the likelihood that the brain will be the first site of symptomatic recurrence [8]. Here, ERBB2 is linked to breast carcinoma.